News | Cardiac Diagnostics | September 13, 2016

New Position Statement Evaluates Role of ECG in Athletic Cardiovascular Screening

Statement acknowledges potential benefits of ECG screening but ultimately recommends personalized approach for individual athletes

AMSSM, American Medical Society for Sports Medicine, cardiovascular screening, athletes, position statement

September 13, 2016 — The American Medical Society for Sports Medicine (AMSSM) last week released a new position statement on cardiovascular pre-participation screening for athletes. The statement discusses current evidence and knowledge gaps while offering recommendations and future directions.

AMSSM formed a task force to address the controversial topic of cardiovascular screening in athletes and the potential addition of an electrocardiogram (ECG) to the standard history and physical examination. The position statement presents several new paradigm shifts in thinking about cardiovascular screening in athletes — namely a reassessment of the current standard, recognition of the differential risk of sudden cardiac arrest and death (SCA/D) in different athlete populations, a new framework to assist physicians when considering a screening ECG and respect for physician autonomy to choose the most appropriate screening strategy.

Developed by an expert panel of primary care sports medicine physicians representing all perspectives on cardiovascular screening, the statement provides a balanced assessment of the current evidence and knowledge gaps regarding cardiovascular screening in athletes. The position statement is concurrently being published in the Clinical Journal of Sport Medicine, the British Journal of Sports Medicine and Current Sports Medicine Reports.

The primary goal of cardiovascular screening in competitive athletes is to identify cardiac disorders at elevated risk of SCA/D and to reduce morbidity and mortality through individualized and disease-specific management. The current pre-participation history and physical examination, while pragmatic and widely practiced, is limited in its ability to identify athletes with conditions at risk for SCA/D.

ECG screening does offer enhanced detection of cardiac disorders at potential risk of SCA/D, but it also increases the potential for false-positive results and the associated downstream consequences. “Evidence suggests medical management can reduce the risk of sudden death for several of the cardiac disorders we are looking for. The question is whether we can accomplish early detection and proper management without causing undue harm,” said Jonathan Drezner, M.D., lead author and co-chair of the statement and an AMSSM past president. In choosing a screening strategy, sports medicine physicians should consider the individual risk of the athlete, physician expertise and available cardiology resources for accurate ECG interpretation and the secondary evaluation of ECG abnormalities, as well as their assessment that a particular screening strategy will provide more benefit than harm.

“In the absence of clear evidence, we must respect physician autonomy to implement the most appropriate screening strategy unique to their athlete population and community resources,” stated Fran O’Connor, M.D., MPH, also co-chair of the statement and an AMSSM past president. Widely practiced and accepted screening standards are not perfect and should undergo continual revision as new data emerges.

ECG screening is often framed as a choice between universal, mandatory screening or no screening at all. “A single, universal strategy or ‘one-size-fits-all’ model may not be appropriate for all athletes or all physicians,” Drezner added. Accordingly, AMSSM supports continued research in this area to validate the optimal strategies for reducing SCA/D in athletes.

For more information: www.journals.lww.com, www.bjsm.bmj.com

Related Content

Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
High Intensity Exercise in Teenagers Could Ward Off Heart Disease

Ultrasound image of the carotid artery. Lines in yellow were used to determine arterial diameter and stretching before and following exercise.

News | Cardiac Diagnostics | July 16, 2018
New research published in Experimental Physiology has indicated potential differences in heart health benefits of...
News | Cardiac Diagnostics | June 14, 2018
A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the...
The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

 

Feature | Cardiac Diagnostics | May 07, 2018 | Steven D. Freedman, M.D., Ph.D.
 
Overlay Init